Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancerSarah P. Blagden, Johann S. de Bono, Shannon Murray et al.|European Journal of Cancer Supplements|2008Cited by 2